Abstract
The UV-B pain model utilizes ultraviolet light to induce a small area of inflammation allowing assessment of mechanical and thermal thresholds. Pharmacologic testing has mainly focused on reduction of primary hyperalgesia, although the effect of analgesics on secondary hyperalgesia has also been investigated. The model requires an instrument to precisely generate controlled UV-B tissue hyperalgesia. Initially, a minimum dose to induce tissue hyperalgesia is determined; subsequently, dosages are delivered in set quantities. Tissue is then assessed for inflammation using color Doppler imaging or flare measurements. Heat pain thresholds and pain tolerance are often evaluated using a commercially available thermal sensory testing device. Analgesics can be administered to determine the influence on these clinical endpoints.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Harrison GI, Young AR, Mcmahon SB (2004) Ultraviolet radiation-induced inflammation as a model for cutaneous hyperalgesia. J Invest Dermatol 122:183–189
Gustorff B, Anzenhofer S, Sycha T, Lehr S, Kress HG (2004) The sunburn pain model: the stability of primary and secondary hyperalgesia over 10 hours in a crossover setting. Anesth Analg 98:173–177
Koppert W, Brueckl V, Weidner C, Schmelz M (2004) Mechanically induced axon reflex and hyperalgesia in human UV-B burn are reduced by systemic lidocaine. Eur J Pain 8(3):237–244
Koppert W, Likar R, Geisslinger G, Zeck S, Schmelz M, Sittl R (1999) Peripheral antihyperalgesic effect of morphine to heat, but not mechanical, stimulation in healthy volunteers after ultraviolet-B irradiation. Anesth Analg 88:117–122
Gustorff B, Hoechtl K, Sycha T, Felouzis E, Lehr S, Kress HG (2004) The effects of Remifentanil and Gabapentin on hyperalgesia in a new extended inflammatory skin pain model in healthy volunteers. Anesth Analg 98:401–407
Sycha T, Anzenhofer S, Lehr S, Schmetterer L, Chizh B, Eichler HG, Gustorff B (2005) Rofecoxib attenuates both primary and secondary inflammatory hyperalgesia: a randomized, double blinded, placebo controlled crossover trial in the UV-B pain model. Pain 113(3):316–322
Bickel A, Dorfs S, Schmelz M, Forster C, Uhl W, Handwerker HO (1998) Effects of antihyperalgesic drugs on experimentally induced hyperalgesia in main. Pain 76(3):317–325
Chizh BA (2008) Personal Communication
Chizh B, O’Donnell M, Napolitano A, Wang J, Brooke A, Aylott M, Bullman J, Gray EJ, Lai RY, Williams PM, Appleby JM (2007) The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans. Pain 132(1):132–141
OECD (Organisation for Economic Cooperation and Development) (2002) OECD guideline for testing of chemicals No. 404: acute dermal irritation/corrosion. Organisation for Economic Cooperation and Development, Paris, pp 1–13
Hoffmann RT, Schmelz M (1999) Time course of UVA- and UVB-induced inflammation and hyperalgesia in human skin. Eur J Pain 3(2):131–139
Yarnitsky D, Sprecher E, Zaslansky R, Hemli JA (1996) Multiple session experimental pain measurement. Pain 67:327–333
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Modir, J.G., Wallace, M.S. (2010). Human Experimental Pain Models 1: The Ultraviolet Light UV-B Pain Model. In: Szallasi, A. (eds) Analgesia. Methods in Molecular Biology, vol 617. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60327-323-7_12
Download citation
DOI: https://doi.org/10.1007/978-1-60327-323-7_12
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-60327-322-0
Online ISBN: 978-1-60327-323-7
eBook Packages: Springer Protocols